Altimmune Inc
ALT4.110USD
+0.170+4.31%
收盤 11/07, 16:00（美東）報價延遲15分鐘
392.91M總市值
虧損本益比TTM
關於 Altimmune Inc 公司
Altimmune, Inc. 是一家臨牀階段的生物製藥公司，專注於開發肥胖和肝病的治療方法。該公司的主要候選產品 pemvidutide 是一種 GLP-1/胰高血糖素雙受體激動劑，正在開發用於治療肥胖和代謝功能障礙相關脂肪性肝炎 (MASH)。該公司已完成 MOMENTUM II 期肥胖試驗，並正在進行 IMPACT IIb 期 MASH 試驗的研究。該公司還在開發 HepTcell，這是一種針對慢性感染乙型肝炎病毒 (HBV) 患者的免疫治療候選產品。該公司已完成 HepTcell II 期臨牀試驗的招募。其候選產品基於其專有平臺技術，例如基於 EuPort 的肽技術和合成肽技術 - Densigen。該公司的全資子公司包括 Altimmune, LLC、Altimmune UK, Limited、Spitfire Pharma, LLC 和 Altimmune AU Pty, Limited。
Altimmune Inc簡介
公司代碼ALT
公司名稱Altimmune Inc
上市日期Oct 06, 2005
CEODr. Vipin K. Garg, Ph.D.
員工數量59
證券類型Ordinary Share
年結日Oct 06
公司地址910 Clopper Road
城市GAITHERSBURG
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編20878-1361
電話12406541450
網址https://altimmune.com/
公司代碼ALT
上市日期Oct 06, 2005
CEODr. Vipin K. Garg, Ph.D.
Altimmune Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Vipin K. Garg, Ph.D.
Dr. Vipin K. Garg, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
355.08K
--
Mr. Raymond M. (Ray) Jordt
Mr. Raymond M. (Ray) Jordt
Chief Business Officer
Chief Business Officer
36.27K
+3.92%
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Independent Director
Independent Director
26.36K
--
Mr. Gregory L. (Greg) Weaver
Mr. Gregory L. (Greg) Weaver
Chief Financial Officer
Chief Financial Officer
10.00K
--
Brig. Gen. (Retd.) Klaus O. Schafer, M.D.
Brig. Gen. (Retd.) Klaus O. Schafer, M.D.
Independent Director
Independent Director
9.18K
--
Dr. Catherine Angell Sohn, Pharm.D.
Dr. Catherine Angell Sohn, Pharm.D.
Independent Director
Independent Director
1.00K
--
Ms. Linda M. Richardson
Ms. Linda M. Richardson
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Philip L. Hodges
Mr. Philip L. Hodges
Independent Director
Independent Director
--
--
Mr. Jerome Benedict (Jerry) Durso
Mr. Jerome Benedict (Jerry) Durso
Chairman of the Board
Chairman of the Board
--
--
Dr. M. Scot Roberts, Ph.D.
Dr. M. Scot Roberts, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Vipin K. Garg, Ph.D.
Dr. Vipin K. Garg, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
355.08K
--
Mr. Raymond M. (Ray) Jordt
Mr. Raymond M. (Ray) Jordt
Chief Business Officer
Chief Business Officer
36.27K
+3.92%
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Independent Director
Independent Director
26.36K
--
Mr. Gregory L. (Greg) Weaver
Mr. Gregory L. (Greg) Weaver
Chief Financial Officer
Chief Financial Officer
10.00K
--
Brig. Gen. (Retd.) Klaus O. Schafer, M.D.
Brig. Gen. (Retd.) Klaus O. Schafer, M.D.
Independent Director
Independent Director
9.18K
--
Dr. Catherine Angell Sohn, Pharm.D.
Dr. Catherine Angell Sohn, Pharm.D.
Independent Director
Independent Director
1.00K
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 11月4日 週二
更新時間: 11月4日 週二
持股股東
股東類型
持股股東
持股股東
佔比
The Vanguard Group, Inc.
6.11%
BlackRock Institutional Trust Company, N.A.
5.52%
State Street Investment Management (US)
2.64%
Tang Capital Management, LLC
2.64%
Geode Capital Management, L.L.C.
1.86%
其他
81.23%
持股股東
持股股東
佔比
The Vanguard Group, Inc.
6.11%
BlackRock Institutional Trust Company, N.A.
5.52%
State Street Investment Management (US)
2.64%
Tang Capital Management, LLC
2.64%
Geode Capital Management, L.L.C.
1.86%
其他
81.23%
股東類型
持股股東
佔比
Investment Advisor
20.68%
Investment Advisor/Hedge Fund
9.49%
Hedge Fund
7.78%
Research Firm
3.16%
Individual Investor
0.73%
Bank and Trust
0.38%
Pension Fund
0.05%
Insurance Company
0.03%
其他
57.70%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
405
38.06M
36.57%
-11.64M
2025Q2
413
40.03M
49.36%
-12.37M
2025Q1
433
39.51M
48.72%
-15.43M
2024Q4
439
41.91M
54.50%
-15.25M
2024Q3
440
40.83M
57.43%
-21.59M
2024Q2
436
43.67M
61.47%
-20.29M
2024Q1
418
45.76M
64.68%
-11.45M
2023Q4
387
34.44M
49.06%
-14.90M
2023Q3
368
31.34M
59.36%
-25.59M
2023Q2
362
36.16M
68.78%
-25.80M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
5.17M
5.85%
+772.36K
+17.57%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.75M
6.52%
+223.90K
+4.05%
Jun 30, 2025
State Street Investment Management (US)
2.75M
3.12%
-637.93K
-18.81%
Jun 30, 2025
Tang Capital Management, LLC
2.75M
3.12%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
1.93M
2.19%
+229.00K
+13.42%
Jun 30, 2025
Susquehanna International Group, LLP
1.62M
1.84%
+543.68K
+50.53%
Jun 30, 2025
Knoll Capital Management, LLC
1.12M
1.27%
--
--
Jun 30, 2025
Caption Management, LLC
980.78K
1.11%
+941.92K
+2423.62%
Jun 30, 2025
BofA Global Research (US)
716.02K
0.81%
+435.47K
+155.22%
Jun 30, 2025
UBS Financial Services, Inc.
633.56K
0.72%
-94.60K
-12.99%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
Invesco NASDAQ Future Gen 200 ETF
0.48%
Virtus LifeSci Biotech Clinical Trials ETF
0.38%
SPDR S&P Biotech ETF
0.15%
Direxion Daily S&P Biotech Bull 3X Shares
0.08%
Fidelity Enhanced Small Cap ETF
0.06%
iShares Micro-Cap ETF
0.06%
iShares Biotechnology ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
iShares Russell 2000 Growth ETF
0.02%
查看更多
Invesco NASDAQ Future Gen 200 ETF
佔比0.48%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.38%
SPDR S&P Biotech ETF
佔比0.15%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.08%
Fidelity Enhanced Small Cap ETF
佔比0.06%
iShares Micro-Cap ETF
佔比0.06%
iShares Biotechnology ETF
佔比0.03%
Invesco Nasdaq Biotechnology ETF
佔比0.03%
ProShares Ultra Nasdaq Biotechnology
佔比0.03%
iShares Russell 2000 Growth ETF
佔比0.02%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
